Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in:

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance

Authors: Tao Wang, Yong Liu, Junjie Kong, Jun Liu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2024

Login to get access

Abstract

Background

Globally, hepatocellular carcinoma (HCC) is one of the most prevalent and deadly malignant tumors. A recent study proposed disulfidptosis, a novel form of regulated cell death (RCD), offering a new avenue for identifying tumor prognosis biomarkers and developing novel therapeutic targets.

Methods

Based on the expression data of 14 disulfideptosis-related genes extracted from public databases, a new molecular classification of HCC called the “disulfidptosis score” was constructed and its relationship to tumor immunity and prognosis was evaluated.

Results

Based on the expression of disulfideptosis-related genes, we performed cluster analysis on HCC samples from the TCGA cohort, which classified these patients into three clusters: A, B, and C, and the differentially expressed genes of different clusters were analyzed. A disulfidptosis score model was constructed by differentially expressed genes associated with prognosis. Univariate and multivariate COX regression analysis showed that disulfidptosis score was an independent prognostic factor for HCC. In addition, in various disulfidptosis score groups, notable disparities were observed concerning the tumor immune microenvironment as well as the expression of immune checkpoint.

Conclusion

Disulfidptosis score have an important role in predicting HCC prognosis and help guide us in providing better immunotherapy options for patients.
Appendix
Available only for authorised users
Literature
Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8):1537–1544PubMedPubMedCentralCrossRef
Bagchi S, Yuan R, Engleman EG (2021) Immune Checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249PubMedCrossRef
Bai D-S, Zhang C, Chen P, Jin S-J, Jiang G-Q (2017) The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep 7(1):12870PubMedPubMedCentralCrossRef
Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCrossRef
Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D et al (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262PubMedCrossRef
Chen H, Zhang H, Cao L, Cui J, Ma X, Zhao C et al (2022) Glucose limitation sensitizes Cancer cells to Selenite-Induced cytotoxicity via SLC7A11-Mediated Redox Collapse. Cancers (Basel). 14(2)
De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478PubMedPubMedCentralCrossRef
Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81PubMedCrossRef
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D et al (2017) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66(3):545–551PubMedCrossRef
EASL-EORTC clinical (2012) Practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502PubMedPubMedCentralCrossRef
Foerster F, Gairing SJ, Ilyas SI, Galle PR (2022) Emerging immunotherapy for HCC: a guide for hepatologists. Hepatology 75(6):1604–1626PubMedCrossRef
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034PubMedPubMedCentralCrossRef
Furbert-Harris PM, Parish-Gause D, Hunter KA, Vaughn TR, Howland C, Okomo-Awich J et al (2003) Activated eosinophils upregulate the metastasis suppressor molecule E-cadherin on prostate tumor cells. Cell Mol Biol (Noisy-le-grand) 49(7):1009–1016PubMed
Gong L, Huang D, Shi Y, Liang Za, Bu H (2023) Regulated cell death in cancer: from pathogenesis to treatment. Chin Med J (Engl) 136(6):653–665PubMedCrossRef
Grisaru S, Itan M, Munitz A (2021) Analysis of mouse Eosinophil Migration and Killing of Tumor cells. Methods Mol Biol 2241:89–97PubMedCrossRef
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65(3):1089–1096PubMedCrossRef
Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895PubMedPubMedCentralCrossRef
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99(19):12293–12297PubMedPubMedCentralCrossRef
Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B et al (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst. 109(9)
Joly JH, Delfarah A, Phung PS, Parrish S, Graham NA (2020) A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem 295(5):1350–1365PubMedCrossRef
Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A (2004) Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol 23(9):549–560PubMedCrossRef
Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol. 3(11)
Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459–465PubMedCrossRef
Lee Y-T, Fujiwara N, Yang JD, Hoshida Y (2023) Risk stratification and early detection biomarkers for precision HCC screening. Hepatology 78(1):319–362PubMedCrossRef
Liu Y, Zheng P (2020) Preserving the CTLA-4 checkpoint for Safer and more effective Cancer immunotherapy. Trends Pharmacol Sci. 41(1)
Liu X, Olszewski K, Zhang Y, Lim EW, Shi J, Zhang X et al (2020) Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol 22(4):476–486PubMedPubMedCentralCrossRef
Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M et al (2023) Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol 25(3):404–414PubMedPubMedCentralCrossRef
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M et al (2016) Hepatocellular carcinoma. Nat Rev Dis Primers 2:16018PubMedCrossRef
Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout SK (2018) Immunomodulation of the Tumor Microenvironment: turn foe into friend. Front Immunol 9:2909PubMedPubMedCentralCrossRef
Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM et al (2010) Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138(2):493–502PubMedCrossRef
Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione C et al (2017) IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology 6(6):e1317420PubMedPubMedCentralCrossRef
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR et al (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118PubMedCrossRef
Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon H-U et al (2005) 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol 174(1):110–118PubMedCrossRef
Peggs KS, Quezada SA (2010) Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev Anticancer Ther 10(11):1697–1701PubMedCrossRef
Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L et al (2022) Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther 7(1):286PubMedPubMedCentralCrossRef
Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C et al (2019) Activated eosinophils exert antitumorigenic activities in Colorectal Cancer. Cancer Immunol Res 7(3):388–400PubMedCrossRef
Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67PubMedCrossRef
Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A et al (2019) PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol 234(10):16824–16837PubMedCrossRef
Thomas DA, Massagué J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369–380PubMedCrossRef
Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B et al (2022) Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol 15(1):174PubMedPubMedCentralCrossRef
Ullah R, Yin Q, Snell AH, Wan L (2022) RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol 85:123–154PubMedCrossRef
Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537–549PubMedCrossRef
Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12):1572–1573PubMedPubMedCentralCrossRef
Xing M, Wang X, Kiken RA, He L, Zhang J-Y (2021) Immunodiagnostic biomarkers for Hepatocellular Carcinoma (HCC): the first step in detection and treatment. Int J Mol Sci. 22(11)
Xu Y, Lv D, Yan C, Su H, Zhang X, Shi Y et al (2022) METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification. Cancer Cell Int 22(1):11PubMedPubMedCentralCrossRef
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28PubMedPubMedCentralCrossRef
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612PubMedCrossRef
Yu L, Wei J, Liu P (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 85:69–94PubMedCrossRef
Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L et al (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 40(1):184PubMedPubMedCentralCrossRef
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940–952PubMedCrossRef
Metadata
Title
Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance
Authors
Tao Wang
Yong Liu
Junjie Kong
Jun Liu
Publication date
01-12-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-024-06031-7

Other articles of this Issue 12/2024

The impact of setup errors on dose distribution in cervical cancer radiotherapy and the margin from CTV to PTV

The role of the SOX2 gene in cervical cancer: focus on ferroptosis and construction of a predictive model

  • Open Access
  • Research

Dosimetric evaluation of different cylinder diameters in three-dimensional vaginal brachytherapy for early-stage endometrial cancer

TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis

Retraction Note: Primary hemostasis dysfunctions and bleeding risk in newly diagnosed acute myeloid leukemia

  • Open Access
  • Retraction Note

Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits